BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carbajo-Lozoya J, Ma-Lauer Y, Malešević M, Theuerkorn M, Kahlert V, Prell E, von Brunn B, Muth D, Baumert TF, Drosten C, Fischer G, von Brunn A. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res 2014;184:44-53. [PMID: 24566223 DOI: 10.1016/j.virusres.2014.02.010] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Magro F, Rahier JF, Abreu C, MacMahon E, Hart A, van der Woude CJ, Gordon H, Adamina M, Viget N, Vavricka S, Kucharzik T, Leone S, Siegmund B, Danese S, Peyrin-Biroulet L. Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. J Crohns Colitis. 2020;14:S798-S806. [PMID: 32722754 DOI: 10.1093/ecco-jcc/jjaa160] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
2 Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Sweet AN, André NM, Stout AE, Licitra BN, Whittaker GR. Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP). Viruses 2022;14:481. [DOI: 10.3390/v14030481] [Reference Citation Analysis]
4 Cure E, Kucuk A, Cumhur Cure M. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19). Rheumatol Int 2020;40:1177-9. [PMID: 32415310 DOI: 10.1007/s00296-020-04603-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
5 von Hahn T, Ciesek S. Cyclophilin polymorphism and virus infection. Curr Opin Virol 2015;14:47-9. [PMID: 26281011 DOI: 10.1016/j.coviro.2015.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
6 Lai Q, Spoletini G, Bianco G, Graceffa D, Agnes S, Rossi M, Lerut J. SARS-CoV2 and immunosuppression: A double-edged sword. Transpl Infect Dis 2020;22:e13404. [PMID: 32639598 DOI: 10.1111/tid.13404] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
7 Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer Y, Caly L, Druce J, de Vries JJC, Kikkert M, Bárcena M, Sidorov I, Snijder EJ. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J Gen Virol 2020;101:925-40. [PMID: 32568027 DOI: 10.1099/jgv.0.001453] [Cited by in Crossref: 170] [Cited by in F6Publishing: 151] [Article Influence: 85.0] [Reference Citation Analysis]
8 Tseng HT, Wu XC, Huang CY, Shih CM, Lin YW, Lin FY. The Impact of SARS-CoV-2 Infection, and Application of Immunosuppressive Agents in Kidney Transplant Recipients Suffering from COVID-19. Pharmaceuticals (Basel) 2021;14:1054. [PMID: 34681278 DOI: 10.3390/ph14101054] [Reference Citation Analysis]
9 Cherian SS, Agrawal M, Basu A, Abraham P, Gangakhedkar RR, Bhargava B. Perspectives for repurposing drugs for the coronavirus disease 2019. Indian J Med Res 2020;151:160-71. [PMID: 32317408 DOI: 10.4103/ijmr.IJMR_585_20] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
10 Gallardo-Flores CE, Colpitts CC. Cyclophilins and Their Roles in Hepatitis C Virus and Flavivirus Infections: Perspectives for Novel Antiviral Approaches. Pathogens 2021;10:902. [PMID: 34358052 DOI: 10.3390/pathogens10070902] [Reference Citation Analysis]
11 de Wilde AH, Pham U, Posthuma CC, Snijder EJ. Cyclophilins and cyclophilin inhibitors in nidovirus replication. Virology 2018;522:46-55. [PMID: 30014857 DOI: 10.1016/j.virol.2018.06.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
12 Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M, Herbst A, Kirsner RS. Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19. Clin Dermatol 2020;38:775-80. [PMID: 32419721 DOI: 10.1016/j.clindermatol.2020.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Craig-Schapiro R, Salinas T, Lubetzky M, Abel BT, Sultan S, Lee JR, Kapur S, Aull MJ, Dadhania DM. COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients. Am J Transplant 2021;21:1576-85. [PMID: 33043597 DOI: 10.1111/ajt.16351] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
14 Harak C, Lohmann V. Ultrastructure of the replication sites of positive-strand RNA viruses. Virology 2015;479-480:418-33. [PMID: 25746936 DOI: 10.1016/j.virol.2015.02.029] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 13.0] [Reference Citation Analysis]
15 Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020;159:350-357. [PMID: 32283100 DOI: 10.1053/j.gastro.2020.04.012] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 53.0] [Reference Citation Analysis]
16 Li X, Peng T. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. Front Pharmacol 2021;12:660710. [PMID: 34017257 DOI: 10.3389/fphar.2021.660710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Song LG, Xie QX, Lao HL, Lv ZY. Human coronaviruses and therapeutic drug discovery. Infect Dis Poverty 2021;10:28. [PMID: 33726861 DOI: 10.1186/s40249-021-00812-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Azad AKM, Fatima S, Capraro A, Waters SA, Vafaee F. Integrative resource for network-based investigation of COVID-19 combinatoric drug repositioning and mechanism of action. Patterns (N Y) 2021;:100325. [PMID: 34278363 DOI: 10.1016/j.patter.2021.100325] [Reference Citation Analysis]
19 Prasad K, Ahamad S, Kanipakam H, Gupta D, Kumar V. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine. ACS Chem Neurosci 2021;12:930-44. [PMID: 33606519 DOI: 10.1021/acschemneuro.1c00019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Li X, Zhang L, Chen S, Ouyang H, Ren L. Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses. Microorganisms 2021;9:1479. [PMID: 34361915 DOI: 10.3390/microorganisms9071479] [Reference Citation Analysis]
21 de Almeida SMV, Santos Soares JC, Dos Santos KL, Alves JEF, Ribeiro AG, Jacob ÍTT, da Silva Ferreira CJ, Dos Santos JC, de Oliveira JF, de Carvalho Junior LB, de Lima MDCA. COVID-19 therapy: What weapons do we bring into battle? Bioorg Med Chem 2020;28:115757. [PMID: 32992245 DOI: 10.1016/j.bmc.2020.115757] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
22 Sauerhering L, Kupke A, Meier L, Dietzel E, Hoppe J, Gruber AD, Gattenloehner S, Witte B, Fink L, Hofmann N, Zimmermann T, Goesmann A, Nist A, Stiewe T, Becker S, Herold S, Peteranderl C. Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus via interferon-λ in vitro and in mice. Eur Respir J 2020;56:1901826. [PMID: 32616594 DOI: 10.1183/13993003.01826-2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
23 Hage R, Steinack C, Benden C, Schuurmans M. COVID-19 in Patients with Solid Organ Transplantation: A Systematic Review. Transplantology 2020;1:1-15. [DOI: 10.3390/transplantology1010001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 7.5] [Reference Citation Analysis]
24 AbdulRahim N, McAdams M, Xu P, Wojciechowski D, La Hoz RM, Lu C, Vazquez MA, Hedayati SS. Association of Inflammatory Biomarkers with Immunosuppression Management and Outcomes in Kidney Transplant Recipients with COVID-19. Transplant Proc 2021;53:2451-67. [PMID: 34465422 DOI: 10.1016/j.transproceed.2021.08.002] [Reference Citation Analysis]
25 von Brunn A, Ciesek S, von Brunn B, Carbajo-Lozoya J. Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication. Curr Opin Virol 2015;14:56-61. [PMID: 26318518 DOI: 10.1016/j.coviro.2015.08.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
26 Huang T, Sun L, Kang D, Poongavanam V, Liu X, Zhan P, Menéndez-Arias L. Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. Adv Exp Med Biol 2021;1322:219-60. [PMID: 34258743 DOI: 10.1007/978-981-16-0267-2_9] [Reference Citation Analysis]
27 Liang W, Zhang Y, Li M, Al-Shaebi F, Li J, Zhang J, Wei L. Cyclophilin A Inhibits Human Respiratory Syncytial Virus (RSV) Replication by Binding to RSV-N through Its PPIase Activity. J Virol 2021;95:e0056321. [PMID: 34011546 DOI: 10.1128/JVI.00563-21] [Reference Citation Analysis]
28 Spini A, Giudice V, Brancaleone V, Morgese MG, De Francia S, Filippelli A, Ruggieri A, Ziche M, Ortona E, Cignarella A, Trabace L. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. Pharmacol Res 2021;173:105848. [PMID: 34454035 DOI: 10.1016/j.phrs.2021.105848] [Reference Citation Analysis]
29 Scharringa S, Hoffman T, van Kessel DA, Rijkers GT. Vaccination and their importance for lung transplant recipients in a COVID-19 world. Expert Rev Clin Pharmacol 2021;:1-13. [PMID: 34328054 DOI: 10.1080/17512433.2021.1961577] [Reference Citation Analysis]
30 Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, Meyer B, Kusov Y, von Brunn B, Bairad DR, Hünten S, Drosten C, Hermeking H, Leonhardt H, Mann M, Hilgenfeld R, von Brunn A. p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc Natl Acad Sci U S A 2016;113:E5192-201. [PMID: 27519799 DOI: 10.1073/pnas.1603435113] [Cited by in Crossref: 77] [Cited by in F6Publishing: 81] [Article Influence: 12.8] [Reference Citation Analysis]
31 Ma-Lauer Y, Zheng Y, Malešević M, von Brunn B, Fischer G, von Brunn A. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res 2020;173:104620. [PMID: 31634494 DOI: 10.1016/j.antiviral.2019.104620] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
32 Molyvdas A, Matalon S. Cyclosporine: an old weapon in the fight against coronaviruses. Eur Respir J 2020;56:2002484. [PMID: 32732332 DOI: 10.1183/13993003.02484-2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
33 de Wilde AH, Zevenhoven-Dobbe JC, Beugeling C, Chatterji U, de Jong D, Gallay P, Szuhai K, Posthuma CC, Snijder EJ. Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture. Virology 2018;517:148-56. [PMID: 29249267 DOI: 10.1016/j.virol.2017.11.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
34 Tschopp J, L'Huillier AG, Mombelli M, Mueller NJ, Khanna N, Garzoni C, Meloni D, Papadimitriou-Olivgeris M, Neofytos D, Hirsch HH, Schuurmans MM, Müller T, Berney T, Steiger J, Pascual M, Manuel O, van Delden C; Swiss Transplant Cohort Study (STCS). First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. Am J Transplant 2020;20:2876-82. [PMID: 32412159 DOI: 10.1111/ajt.16062] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 27.0] [Reference Citation Analysis]
35 Evans JP, Liu SL. Role of host factors in SARS-CoV-2 entry. J Biol Chem 2021;297:100847. [PMID: 34058196 DOI: 10.1016/j.jbc.2021.100847] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
36 Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, von Brunn A, Leyssen P, Lanko K, Neyts J, de Wilde A, Snijder EJ, Liu H, Hilgenfeld R. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. J Med Chem 2020;63:4562-78. [PMID: 32045235 DOI: 10.1021/acs.jmedchem.9b01828] [Cited by in Crossref: 212] [Cited by in F6Publishing: 191] [Article Influence: 106.0] [Reference Citation Analysis]
37 Liao Y, Luo D, Peng K, Zeng Y. Cyclophilin A: a key player for etiological agent infection. Appl Microbiol Biotechnol 2021;105:1365-77. [PMID: 33492451 DOI: 10.1007/s00253-021-11115-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Dittmar M, Lee JS, Whig K, Segrist E, Li M, Kamalia B, Castellana L, Ayyanathan K, Cardenas-Diaz FL, Morrisey EE, Truitt R, Yang W, Jurado K, Samby K, Ramage H, Schultz DC, Cherry S. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep 2021;35:108959. [PMID: 33811811 DOI: 10.1016/j.celrep.2021.108959] [Cited by in Crossref: 27] [Cited by in F6Publishing: 38] [Article Influence: 27.0] [Reference Citation Analysis]
39 [DOI: 10.1101/2020.06.19.161042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
40 Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Antimicrob Agents Chemother 2020;64:e00876-20. [PMID: 32376613 DOI: 10.1128/AAC.00876-20] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
41 [DOI: 10.1101/2020.04.20.049924] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
42 Aryal S, Hsu HM, Lou YC, Chu CH, Tai JH, Hsu CH, Chen C. N-Terminal Segment of TvCyP2 Cyclophilin from Trichomonas vaginalis Is Involved in Self-Association, Membrane Interaction, and Subcellular Localization. Biomolecules 2020;10:E1239. [PMID: 32859063 DOI: 10.3390/biom10091239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 de Lima Menezes G, da Silva RA. Identification of potential drugs against SARS-CoV-2 non-structural protein 1 (nsp1). J Biomol Struct Dyn 2020;:1-11. [PMID: 32657643 DOI: 10.1080/07391102.2020.1792992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
44 Hoek RAS, Manintveld OC, Betjes MGH, Hellemons ME, Seghers L, Van Kampen JAA, Caliskan K, van de Wetering J, van den Hoogen M, Metselaar HJ, Hesselink DA; Rotterdam Transplant Group. COVID-19 in solid organ transplant recipients: a single-center experience. Transpl Int 2020;33:1099-105. [PMID: 32460390 DOI: 10.1111/tri.13662] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 26.0] [Reference Citation Analysis]
45 Russell B, Moss C, George G, Santaolalla A, Cope A, Papa S, Van Hemelrijck M. Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022. [PMID: 32256705 DOI: 10.3332/ecancer.2020.1022] [Cited by in Crossref: 209] [Cited by in F6Publishing: 211] [Article Influence: 104.5] [Reference Citation Analysis]
46 Decker A, Welzel M, Laubner K, Grundmann S, Kochs G, Panning M, Thimme R, Bode C, Wagner D, Lother A. Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation. Am J Transplant 2020;20:3239-45. [PMID: 32519406 DOI: 10.1111/ajt.16133] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
47 Farhat Ullah M, Ali Y, Ramzan Khan M, Ullah Khan I, Yan B, Ijaz Khan M, Malik MY. A review of COVID-19: Treatment Strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. Saudi J Biol Sci 2021. [PMID: 34658640 DOI: 10.1016/j.sjbs.2021.10.020] [Reference Citation Analysis]
48 AlOtaibi TM, Gheith OA, Abuelmagd MM, Adel M, Alqallaf AK, Elserwy NA, Shaker M, Abbas AM, Nagib AM, Nair P, Halim MA, Mahmoud T, Khaled MM, Hammad MA, Fayyad ZA, Atta AF, Mostafa AY, Draz AS, Zakaria ZE, Atea KA, Aboatya HH, Ameenn ME, Monem MA, Mahmoud AM. Better outcome of COVID-19 positive kidney transplant recipients during the unremitting stage with optimized anticoagulation and immunosuppression. Clin Transplant 2021;35:e14297. [PMID: 33768630 DOI: 10.1111/ctr.14297] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Devaux CA, Melenotte C, Piercecchi-Marti MD, Delteil C, Raoult D. Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19? Front Med (Lausanne) 2021;8:663708. [PMID: 34552938 DOI: 10.3389/fmed.2021.663708] [Reference Citation Analysis]
50 Aminpour M, Cannariato M, Preto J, Safaeeardebili ME, Moracchiato A, Doria D, Donato F, Zizzi EA, Deriu MA, Scheim DE, Santin AD, Tuszynski JA. In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds. Computation 2022;10:51. [DOI: 10.3390/computation10040051] [Reference Citation Analysis]
51 Sanclemente-Alaman I, Moreno-Jiménez L, Benito-Martín MS, Canales-Aguirre A, Matías-Guiu JA, Matías-Guiu J, Gómez-Pinedo U. Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2. Front Immunol 2020;11:2163. [PMID: 32983181 DOI: 10.3389/fimmu.2020.02163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
52 Pawlotsky JM. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. Clin Infect Dis 2020;71:2191-4. [PMID: 32409832 DOI: 10.1093/cid/ciaa587] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
53 Redzic JS, Lee E, Born A, Issaian A, Henen MA, Nichols PJ, Blue A, Hansen KC, D'Alessandro A, Vögeli B, Eisenmesser EZ. The Inherent Dynamics and Interaction Sites of the SARS-CoV-2 Nucleocapsid N-Terminal Region. J Mol Biol 2021;433:167108. [PMID: 34161778 DOI: 10.1016/j.jmb.2021.167108] [Reference Citation Analysis]
54 Tanaka Y, Sato Y, Sasaki T. Feline coronavirus replication is affected by both cyclophilin A and cyclophilin B. J Gen Virol 2017;98:190-200. [PMID: 27902373 DOI: 10.1099/jgv.0.000663] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
55 de Wilde AH, Falzarano D, Zevenhoven-Dobbe JC, Beugeling C, Fett C, Martellaro C, Posthuma CC, Feldmann H, Perlman S, Snijder EJ. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Res 2017;228:7-13. [PMID: 27840112 DOI: 10.1016/j.virusres.2016.11.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
56 de Sandes-Freitas TV, Cristelli MP, Requião-Moura LR, Modelli de Andrade LG, Viana LA, Garcia VD, de Oliveira CMC, Esmeraldo RM, de Lima PR, Charpiot IMMF, Ferreira TCA, Franco RF, Costa KMAH, Simão DR, Ferreira GF, Santana VBBM, Almeida RAMB, Deboni LM, Saldanha ALDR, Noronha IL, de Oliveira LC, de Carvalho DBM, Oriá RB, Medina-Pestana JO, Tedesco-Silva Junior H. Temporal Reduction in COVID-19-Associated Fatality Among Kidney Transplant Recipients: The Brazilian COVID-19 Registry Cohort Study. Transpl Int 2022;36:10205. [PMID: 35185380 DOI: 10.3389/ti.2022.10205] [Reference Citation Analysis]
57 Ulu S, Gungor O, Gok Oguz E, Hasbal NB, Turgut D, Arici M. COVID-19: a novel menace for the practice of nephrology and how to manage it with minor devastation? Ren Fail 2020;42:710-25. [PMID: 32713282 DOI: 10.1080/0886022X.2020.1797791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
58 Tanaka Y, Amano A, Morisaki M, Sato Y, Sasaki T. Cellular peptidyl-prolyl cis/trans isomerase Pin1 facilitates replication of feline coronavirus. Antiviral Res 2016;126:1-7. [PMID: 26675666 DOI: 10.1016/j.antiviral.2015.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
59 Ruiz I. Beneficial Effect of Tacrolimus… Cyclosporin A, Still up for Discussion! Gastroenterology 2021;161:730-1. [PMID: 33631182 DOI: 10.1053/j.gastro.2021.02.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Liu C, von Brunn A, Zhu D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med Drug Discov 2020;7:100056. [PMID: 32835213 DOI: 10.1016/j.medidd.2020.100056] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
61 Lei J, Ma-Lauer Y, Han Y, Thoms M, Buschauer R, Jores J, Thiel V, Beckmann R, Deng W, Leonhardt H, Hilgenfeld R, von Brunn A. The SARS-unique domain (SUD) of SARS-CoV and SARS-CoV-2 interacts with human Paip1 to enhance viral RNA translation. EMBO J 2021;40:e102277. [PMID: 33876849 DOI: 10.15252/embj.2019102277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
62 Esmaeilzadeh A, Jafari D, Tahmasebi S, Elahi R, Khosh E. Immune-Based Therapy for COVID-19. Adv Exp Med Biol 2021;1318:449-68. [PMID: 33973194 DOI: 10.1007/978-3-030-63761-3_26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2018;419:1-42. [PMID: 28643204 DOI: 10.1007/82_2017_25] [Cited by in Crossref: 106] [Cited by in F6Publishing: 144] [Article Influence: 35.3] [Reference Citation Analysis]
64 Lubetzky M, Aull MJ, Craig-Schapiro R, Lee JR, Marku-Podvorica J, Salinas T, Gingras L, Lee JB, Sultan S, Kodiyanplakkal RP, Hartono C, Saal S, Muthukumar T, Kapur S, Suthanthiran M, Dadhania DM. Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center. Nephrol Dial Transplant 2020;35:1250-61. [PMID: 32678882 DOI: 10.1093/ndt/gfaa154] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
65 Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327-347. [PMID: 26868298 DOI: 10.1038/nrd.2015.37] [Cited by in Crossref: 849] [Cited by in F6Publishing: 775] [Article Influence: 141.5] [Reference Citation Analysis]
66 Anders HJ, Bruchfeld A, Fernandez Juarez GM, Floege J, Goumenos D, Turkmen K, van Kooten C, Tesar V, Segelmark M. Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. Nephrol Dial Transplant 2020;35:920-5. [PMID: 32445573 DOI: 10.1093/ndt/gfaa112] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
67 Dash P, Mohapatra S, Ghosh S, Nayak B. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. Front Pharmacol 2020;11:590154. [PMID: 33815095 DOI: 10.3389/fphar.2020.590154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
68 Almasi F, Mohammadipanah F. Hypothetical targets and plausible drugs of coronavirus infection caused by SARS-CoV-2. Transbound Emerg Dis 2021;68:318-32. [PMID: 32662203 DOI: 10.1111/tbed.13734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
69 de Wilde AH, Boomaars-van der Zanden AL, de Jong AWM, Bárcena M, Snijder EJ, Posthuma CC. Adaptive Mutations in Replicase Transmembrane Subunits Can Counteract Inhibition of Equine Arteritis Virus RNA Synthesis by Cyclophilin Inhibitors. J Virol 2019;93:e00490-19. [PMID: 31243130 DOI: 10.1128/JVI.00490-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Cure E, Kucuk A, Cumhur Cure M. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19). Rheumatol Int 2020;40:1177-9. [PMID: 32415310 DOI: 10.1007/s00296-020-04603-7] [Reference Citation Analysis]
71 Tuli HS, Sood S, Kaur J, Kumar P, Seth P, Punia S, Yadav P, Sharma AK, Aggarwal D, Sak K. Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. 3 Biotech 2021;11:110. [PMID: 33552835 DOI: 10.1007/s13205-021-02644-8] [Reference Citation Analysis]
72 Clark LK, Green TJ, Petit CM. Structure of nonstructural protein 1 from SARS-CoV-2. bioRxiv 2020:2020. [PMID: 33173873 DOI: 10.1101/2020.11.03.366757] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Pierrotti LC, Reusing Junior JO, Freire MP, Barros Machado DJ, Moreira RM, Ventura CG, Litvoc MN, Nahas WC, David‐neto E. COVID‐19 among kidney‐transplant recipients requiring hospitalization: preliminary data and outcomes from a single‐center in Brazil. Transpl Int 2020;33:1837-42. [DOI: 10.1111/tri.13745] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
74 Lin P, Wang M, Wei Y, Kim T, Wei X. Coronavirus in human diseases: Mechanisms and advances in clinical treatment. MedComm (Beijing) 2020. [PMID: 33173860 DOI: 10.1002/mco2.26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
75 Poulsen NN, von Brunn A, Hornum M, Blomberg Jensen M. Cyclosporine and COVID-19: Risk or favorable? Am J Transplant 2020;20:2975-82. [PMID: 32777170 DOI: 10.1111/ajt.16250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
76 L'Huillier AG, Danziger-Isakov L, Chaudhuri A, Green M, Michaels MG, M Posfay-Barbe K, van der Linden D, Verma A, McCulloch M, Ardura MI. SARS-CoV-2 and pediatric solid organ transplantation: Current knowns and unknowns. Pediatr Transplant 2021;25:e13986. [PMID: 33689201 DOI: 10.1111/petr.13986] [Reference Citation Analysis]
77 Schoot TS, Kerckhoffs APM, Hilbrands LB, van Marum RJ. Immunosuppressive Drugs and COVID-19: A Review. Front Pharmacol 2020;11:1333. [PMID: 32982743 DOI: 10.3389/fphar.2020.01333] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
78 Ahmed-Belkacem A, Colliandre L, Ahnou N, Nevers Q, Gelin M, Bessin Y, Brillet R, Cala O, Douguet D, Bourguet W, Krimm I, Pawlotsky JM, Guichou JF. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities. Nat Commun 2016;7:12777. [PMID: 27652979 DOI: 10.1038/ncomms12777] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
79 Yuksel M, Akturk H, Mizikoglu O, Toroslu E, Arikan C. A single-center report of COVID-19 disease course and management in liver transplanted pediatric patients. Pediatr Transplant 2021;:e14061. [PMID: 34076953 DOI: 10.1111/petr.14061] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
80 Hage R, Steinack C, Gautschi F, Schuurmans MM. Transplant Drugs against SARS, MERS and COVID-19. Transplantology 2020;1:71-84. [DOI: 10.3390/transplantology1020007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
81 Clark LK, Green TJ, Petit CM. Structure of Nonstructural Protein 1 from SARS-CoV-2. J Virol 2021;95:e02019-20. [PMID: 33234675 DOI: 10.1128/JVI.02019-20] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
82 Hopkins S, Gallay PA. The role of immunophilins in viral infection. Biochim Biophys Acta 2015;1850:2103-10. [PMID: 25445708 DOI: 10.1016/j.bbagen.2014.11.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
83 García-Juárez I, Campos-Murguía A, Tovar-Méndez VH, Gabutti A, Ruiz I. Unexpected better outcome in a liver transplant recipient with COVID-19: a beneficial effect of tacrolimus? Rev Gastroenterol Mex (Engl Ed) 2020;85:437-42. [PMID: 33032841 DOI: 10.1016/j.rgmx.2020.08.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]